









Markets
/
Stocks
/
nasdaq-wgs
/

GeneDx Holdings Corp

WGS

84.290USD

+0.210+0.25%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

2.44BMarket Cap

776.72P/E TTM



GeneDx Holdings Corp

84.290

+0.210+0.25%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of GeneDx Holdings Corp

Currency: USD Updated: 2026-02-06

Key Insights

GeneDx Holdings Corp's fundamentals are relatively very healthy, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 33 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 170.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

GeneDx Holdings Corp's Score

Industry at a Glance

Industry Ranking

33 / 75

Overall Ranking

174 / 4521

Industry

Healthcare Providers & Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

GeneDx Holdings Corp Highlights

StrengthsRisks

GeneDx Holdings Corp. is a genomics company. The Company operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. It operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. It offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 30.15% year-on-year.

Overvalued

The company’s latest PE is 776.72, at a high 3-year percentile range.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 91.00 shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.10.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

170.000

Target Price

+99.18%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of GeneDx Holdings Corp is 7.88, ranking 40 out of 75 in the Healthcare Providers & Services industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 116.74M, representing a year-over-year increase of 51.86%, while its net profit experienced a year-over-year increase of 8.14%.

Score

Industry at a Glance

Previous score

7.88

Change



Financials

8.99

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

4.98

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

9.02

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

9.03

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.40

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

GeneDx Holdings Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of GeneDx Holdings Corp is 4.11, ranking 74 out of 75 in the Healthcare Providers & Services industry. Its current P/E ratio is 776.72, which is 114.61% below the recent high of 1666.91 and 110.76% above the recent low of -83.57.

Score

Industry at a Glance

Previous score

4.11

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 33/75

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of GeneDx Holdings Corp is 8.44, ranking 16 out of 75 in the Healthcare Providers & Services industry. The average price target is 160.00, with a high of 185.00 and a low of 140.00.

Score

Industry at a Glance

Previous score

8.44

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 9 analysts

Buy

Current Rating

170.000

Target Price

+99.18%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

GeneDx Holdings Corp

WGS

CVS Health Corp

CVS

Teladoc Health Inc

TDOC

HCA Healthcare Inc

HCA

Tenet Healthcare Corp

THC

Universal Health Services Inc

UHS

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of GeneDx Holdings Corp is 6.78, ranking 40 out of 75 in the Healthcare Providers & Services industry. Currently, the stock price is trading between the resistance level at 122.90 and the support level at 63.62, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.78

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-1.358

Sell

RSI(14)

25.167

Sell

STOCH(KDJ)(9,3,3)

12.903

Oversold

ATR(14)

7.251

Low Volatility

CCI(14)

-164.311

Sell

Williams %R

89.204

Oversold

TRIX(12,20)

-1.499

Sell

StochRSI(14)

3.674

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

89.592

Sell

MA10

93.856

Sell

MA20

101.395

Sell

MA50

128.620

Sell

MA100

128.127

Sell

MA200

109.769

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of GeneDx Holdings Corp is 10.00, ranking 1 out of 75 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 113.16%, representing a quarter-over-quarter increase of 6.64%. The largest institutional shareholder is The Vanguard, holding a total of 1.18M shares, representing 4.10% of shares outstanding, with 13.78% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Corvex Management LP

3.06M

Casdin Capital, LLC

3.01M

-1.26%

Icahn School of Medicine at Mount Sinai

1.37M

-49.50%

OPKO Health Inc

1.37M

-36.88%

BlackRock Institutional Trust Company, N.A.

1.32M

+2.97%

William Blair Investment Management, LLC

1.22M

-25.21%

The Vanguard Group, Inc.

Star Investors

1.17M

-0.89%

Goldman Sachs & Company, Inc.

1.00M

+2.94%

Oracle Investment Management, Inc.

889.95K

-3.52%

Summit Partners Public Asset Management, LLC

823.57K

+7.34%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Providers & Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of GeneDx Holdings Corp is 5.49, ranking 41 out of 75 in the Healthcare Providers & Services industry. The company's beta value is 2.04. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. GeneDx Holdings Corp’s latest ESG disclosure is at an average level in the Healthcare Providers & Services industry, showing no material impact on overall risk.